Highlights from PSA: Will Investors Rise Over Reimbursement Hurdles?
This article was originally published in Start Up
Executive Summary
At our September 2009 Pharmaceutical Strategic Alliances meeting, a recurring theme concerned the growing importance of factoring reimbursement hurdles into drug development decisions. Where does that start? In some cases, at Series A.
You may also be interested in...
Pharma: Serious About Change?
Pharmaceutical companies are attempting to solve unprecedented R&D and commercial challenges via business development, emphasizing cheaper, earlier-stage alliances and building up a base in emerging markets. An analysis of dealmaking trends from 2007 to 2010 shows big companies are embracing new kinds of partners, and shifting away from historic areas of interest to pursue hyper-specialty products and generics.
Health Reform Magnifies Payers' Invisible Place At The Licensing Table
Report from Licensing Executives Society meeting: Survey shows many already have taken action oncomparative effectiveness.
Health Reform Magnifies Payers' Invisible Place At The Licensing Table
Report from Licensing Executives Society meeting: Survey shows many already have taken action oncomparative effectiveness.